scPharmaceuticals Inc(NASDAQ:SCPH) 
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug deliv...
Website: http://www.scpharmaceuticals.com
Full Time Employees: 26
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
product revenues | 16,041,000 | 11,752,000 | 12,150,000 | 10,026,000 | 8,054,000 | 6,102,000 | 6,096,000 | 3,796,000 | 1,638,000 | 2,063,000 | |||||||||||||||||||||
operating expenses: | |||||||||||||||||||||||||||||||
cost of product revenues | 5,011,000 | 3,471,000 | 3,965,000 | 3,311,000 | 2,300,000 | 1,785,000 | 1,773,000 | 1,079,000 | 354,000 | 605,000 | |||||||||||||||||||||
research and development | 4,098,000 | 4,631,000 | 3,154,000 | 3,541,000 | 2,677,000 | 2,726,000 | 3,338,000 | 3,421,000 | 2,934,000 | 2,116,000 | 2,326,000 | 3,718,000 | 5,142,000 | 4,347,000 | 4,530,000 | 3,694,000 | 3,807,000 | 4,009,000 | 3,745,000 | 5,119,000 | 5,139,000 | 4,146,000 | 8,318,000 | 4,293,000 | 5,496,000 | 6,524,000 | 3,149,000 | 3,896,000 | 4,855,000 | 4,048,000 | |
selling, general and administrative | 21,226,000 | 21,407,000 | 21,374,000 | 21,320,000 | 17,508,000 | 17,447,000 | 16,242,000 | 14,135,000 | 12,096,000 | 10,896,000 | |||||||||||||||||||||
total operating expenses | 30,335,000 | 29,509,000 | 28,493,000 | 28,172,000 | 22,485,000 | 21,958,000 | 21,353,000 | 18,635,000 | 15,384,000 | 13,617,000 | 9,502,000 | 9,995,000 | 9,421,000 | 7,240,000 | 6,721,000 | 5,905,000 | 6,456,000 | 6,741,000 | 7,170,000 | 8,438,000 | 7,676,000 | 6,649,000 | 10,433,000 | 6,289,000 | 7,335,000 | 8,847,000 | 5,223,000 | 5,841,000 | 9,904,000 | 8,699,000 | |
income from operations | -14,294,000 | -17,757,000 | -16,343,000 | -18,146,000 | -14,431,000 | -15,856,000 | -15,257,000 | -14,839,000 | -13,746,000 | -11,554,000 | -9,502,000 | -9,995,000 | -9,421,000 | -7,240,000 | -6,721,000 | -5,905,000 | -6,456,000 | -6,741,000 | -7,170,000 | -8,438,000 | -7,676,000 | -6,649,000 | -10,433,000 | -6,289,000 | -7,335,000 | -8,847,000 | -5,223,000 | -5,841,000 | -9,904,000 | -8,699,000 | |
yoy | -0.95% | 11.99% | 7.12% | 22.29% | 4.98% | 37.23% | 60.57% | 48.46% | 45.91% | 59.59% | 41.38% | 69.26% | 45.93% | 7.40% | -6.26% | -30.02% | -15.89% | 1.38% | -31.28% | 34.17% | 4.65% | -24.84% | 99.75% | 7.67% | -25.94% | 1.70% | |||||
qoq | -19.50% | 8.65% | -9.94% | 25.74% | -8.99% | 3.93% | 2.82% | 7.95% | 18.97% | 21.60% | -4.93% | 6.09% | 30.12% | 7.72% | 13.82% | -8.53% | -4.23% | -5.98% | -15.03% | 9.93% | 15.45% | -36.27% | 65.89% | -14.26% | -17.09% | 69.39% | -10.58% | -41.02% | 13.85% | ||
change in fair value of term loan | -150,000 | 300,000 | -251,000 | -2,954,000 | |||||||||||||||||||||||||||
change in fair value of revenue purchase and sale liability | -2,560,000 | -1,752,000 | -1,812,000 | -1,830,000 | |||||||||||||||||||||||||||
other income | -128,000 | 136,000 | 46,000 | 1,804,000 | -1,189,000 | 2,972,000 | 2,412,000 | -36,000 | 239,000 | 990,000 | 1,363,000 | -22,000 | 64,000 | 14,000 | 17,000 | 10,000 | 33,000 | 255,000 | 9,000 | 19,000 | -45,000 | 83,000 | 2,000 | -5,000 | -11,000 | -42,000 | |||||
interest income | 509,000 | 716,000 | 1,000,000 | 903,000 | 664,000 | 877,000 | 1,125,000 | 1,301,000 | 1,363,000 | 1,315,000 | 850,000 | 232,000 | 107,000 | 13,000 | 7,000 | 10,000 | 12,000 | 20,000 | 34,000 | 36,000 | 21,000 | 224,000 | 310,000 | 397,000 | 463,000 | 490,000 | 491,000 | 445,000 | 424,000 | 351,000 | |
interest expense | -1,401,000 | -1,385,000 | -1,485,000 | -1,850,000 | -2,134,000 | -2,101,000 | -2,092,000 | -2,060,000 | -2,010,000 | -1,961,000 | -1,959,000 | -377,000 | -447,000 | -518,000 | -621,000 | -667,000 | -651,000 | -636,000 | -657,000 | -655,000 | -639,000 | -636,000 | -646,000 | -398,000 | -369,000 | -354,000 | -370,000 | -360,000 | -359,000 | -342,000 | |
net income | -18,024,000 | -19,742,000 | -18,845,000 | -35,105,000 | -17,090,000 | -14,108,000 | -13,812,000 | -15,634,000 | -14,154,000 | -11,210,000 | -9,248,000 | -10,162,000 | -9,697,000 | -7,731,000 | -7,318,000 | -6,552,000 | -7,062,000 | -7,102,000 | -7,784,000 | -9,038,000 | |||||||||||
yoy | 5.47% | 39.93% | 36.44% | 124.54% | 20.74% | 25.85% | 49.35% | 53.85% | 45.96% | 45.00% | 26.37% | 55.10% | 37.31% | 8.86% | -5.99% | -27.51% | |||||||||||||||
qoq | -8.70% | 4.76% | -46.32% | 105.41% | 21.14% | 2.14% | -11.65% | 10.46% | 26.26% | 21.22% | -8.99% | 4.80% | 25.43% | 5.64% | 11.69% | -7.22% | -0.56% | -8.76% | -13.87% | ||||||||||||
net income per share | -0.34 | -0.37 | -0.31 | -0.75 | -0.44 | -0.36 | -0.35 | -0.41 | -0.36 | -0.3 | -0.29 | -0.37 | -0.35 | -0.28 | -0.26 | -0.24 | -0.26 | -0.26 | -0.28 | -0.33 | -0.36 | -0.35 | -0.58 | -0.33 | -0.39 | -0.47 | -0.28 | -0.31 | -0.53 | -0.47 | |
weighted-average common shares outstanding — basic and diluted | 53,719,662 | 53,676,376 | 46,558,474 | 38,984,745 | 38,952,131 | 38,760,895 | 38,692,624 | 37,800,960 | 27,401,060 | 27,378,507 | 27,368,354 | 27,355,454 | 27,355,454 | 27,336,724 | 27,319,465 | 23,355,418 | 20,218,473 | 18,584,327 | 18,580,430 | 18,575,726 | 18,569,289 | 18,549,978 | 18,535,432 | ||||||||
other comprehensive loss: | |||||||||||||||||||||||||||||||
unrealized gain on short-term investments | 0.25 | 1 | 1 | 4 | 32 | 7 | -3 | 1 | |||||||||||||||||||||||
comprehensive loss | -18,024 | -19,742 | -18,845 | -35,105 | -17,090 | -14,107 | -13,811 | -15,630 | -14,168 | -11,234 | -9,216 | -10,155 | -9,700 | -7,734 | -7,320 | -6,552 | -7,061 | -7,104 | -7,791 | -9,030 | |||||||||||
loss on extinguishment of debt | -13,032,000 | ||||||||||||||||||||||||||||||
unrealized loss on short-term investments | -14 | -24 | -3 | -2 | |||||||||||||||||||||||||||
other comprehensive gain: | |||||||||||||||||||||||||||||||
general and administrative | 7,176,000 | 6,277,000 | 4,279,000 | 2,893,000 | 2,191,000 | 2,211,000 | 2,649,000 | 2,732,000 | 3,425,000 | 3,319,000 | 2,537,000 | 2,503,000 | 2,115,000 | 1,996,000 | 1,839,000 | 2,323,000 | 2,074,000 | 1,945,000 | 5,049,000 | 4,651,000 | |||||||||||
unrealized gain on short term investments | 2 | 8 | |||||||||||||||||||||||||||||
other expense | -1,000 | -31,000 | -14,000 | -8,000 | |||||||||||||||||||||||||||
net loss and comprehensive loss | -8,295,000 | -7,092,000 | -10,814,000 | -6,207,000 | -7,255,000 | -8,719,000 | -5,100,000 | -5,761,000 | -9,850,000 | -8,732,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||
current assets | ||||||||||||||||||||||||||||||
cash and cash equivalents | 40,809,000 | 57,544,000 | 75,655,000 | 91,484,000 | 38,504,000 | 58,447,000 | 46,814,000 | 35,042,000 | 71,350,000 | 75,453,000 | 71,061,000 | 41,289,000 | 41,178,000 | 51,630,000 | 74,268,000 | 79,323,000 | 74,969,000 | 75,837,000 | 71,819,000 | 44,278,000 | 78,860,000 | 75,339,000 | 72,624,000 | 83,562,000 | 79,467,000 | 83,378,000 | 89,478,000 | 95,299,000 | ||
accounts receivable | 19,409,000 | 13,854,000 | 11,721,000 | 9,217,000 | 6,116,000 | 5,772,000 | 4,489,000 | 4,175,000 | 1,610,000 | 3,004,000 | ||||||||||||||||||||
inventory | 14,573,000 | 14,141,000 | 13,903,000 | 18,107,000 | 15,308,000 | 9,572,000 | 8,840,000 | 7,123,000 | 5,832,000 | 3,621,000 | 1,230,000 | |||||||||||||||||||
prepaid expenses | 3,654,000 | 3,460,000 | 3,549,000 | 3,373,000 | 2,330,000 | 2,198,000 | 2,436,000 | 1,579,000 | 1,835,000 | 2,685,000 | 2,282,000 | 1,643,000 | 1,673,000 | 2,567,000 | 2,791,000 | 1,621,000 | 2,396,000 | 2,637,000 | 2,610,000 | 1,091,000 | 2,897,000 | 3,370,000 | 2,619,000 | 894,000 | 1,658,000 | 1,770,000 | 1,757,000 | 981,000 | 1,608,000 | 1,323,000 |
deposits and other current assets | 284,000 | 354,000 | 1,021,000 | 1,148,000 | 373,000 | 536,000 | 1,160,000 | 1,264,000 | 1,420,000 | 1,286,000 | 1,428,000 | |||||||||||||||||||
total current assets | 78,729,000 | 89,353,000 | 105,849,000 | 123,329,000 | 62,631,000 | 76,525,000 | 92,938,000 | 104,339,000 | 113,574,000 | 126,667,000 | 123,308,000 | 47,169,000 | 57,855,000 | 68,226,000 | 78,275,000 | 86,470,000 | 92,492,000 | 99,066,000 | 107,826,000 | 115,688,000 | 122,536,000 | 79,073,000 | 75,647,000 | 84,887,000 | 81,773,000 | 85,811,000 | 91,893,000 | 96,831,000 | 102,965,000 | 111,568,000 |
property and equipment | 48,000 | 52,000 | 56,000 | 51,000 | 47,000 | 52,000 | 58,000 | 39,000 | 45,000 | 48,000 | 54,000 | 62,000 | 57,000 | 66,000 | 69,000 | 77,000 | 77,000 | 85,000 | 93,000 | 102,000 | 110,000 | 119,000 | 127,000 | 136,000 | 145,000 | 154,000 | 164,000 | 215,000 | 225,000 | 193,000 |
right-of-use lease assets - operating | 1,175,000 | 1,236,000 | 1,273,000 | 1,330,000 | 1,309,000 | 1,355,000 | 1,401,000 | 1,535,000 | 363,000 | 466,000 | 566,000 | 677,000 | 785,000 | 318,000 | 410,000 | 513,000 | 616,000 | 717,000 | 815,000 | 910,000 | 1,002,000 | 1,092,000 | 1,179,000 | 1,264,000 | 1,347,000 | 1,427,000 | ||||
deposits and other assets | 303,000 | 322,000 | 341,000 | 359,000 | 1,471,000 | 522,000 | 82,000 | 188,000 | 189,000 | 190,000 | 267,000 | 310,000 | 283,000 | 283,000 | 283,000 | 289,000 | 248,000 | 243,000 | 132,000 | 78,000 | 89,000 | 22,000 | 148,000 | 197,000 | 12,000 | 13,000 | 10,000 | 9,000 | 8,000 | 7,000 |
total assets | 80,255,000 | 90,963,000 | 107,519,000 | 125,069,000 | 65,458,000 | 78,454,000 | 94,479,000 | 106,101,000 | 114,171,000 | 127,371,000 | 124,195,000 | 48,400,000 | 59,162,000 | 68,893,000 | 79,037,000 | 87,531,000 | 93,615,000 | 100,293,000 | 109,048,000 | 116,960,000 | 123,919,000 | 80,488,000 | 77,283,000 | 86,666,000 | 83,459,000 | 87,587,000 | 93,755,000 | 98,819,000 | 105,009,000 | 113,652,000 |
liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||
current liabilities | ||||||||||||||||||||||||||||||
accounts payable | 4,026,000 | 4,988,000 | 3,883,000 | 5,003,000 | 5,294,000 | 2,706,000 | 4,001,000 | 3,370,000 | 1,182,000 | 1,626,000 | 1,518,000 | 996,000 | 982,000 | 445,000 | 544,000 | 447,000 | 531,000 | 753,000 | 1,666,000 | 839,000 | 770,000 | 652,000 | 1,142,000 | 542,000 | 1,419,000 | 221,000 | 587,000 | 1,667,000 | 2,358,000 | 1,519,000 |
accrued expenses | 16,082,000 | 10,858,000 | 10,702,000 | 9,868,000 | 7,399,000 | 9,206,000 | 8,901,000 | 7,109,000 | 5,120,000 | 5,561,000 | 5,289,000 | 5,178,000 | 4,126,000 | 3,477,000 | 3,995,000 | 3,484,000 | 3,579,000 | 3,585,000 | 4,787,000 | 5,910,000 | 4,724,000 | 3,590,000 | 3,688,000 | 7,169,000 | 7,110,000 | 5,474,000 | 2,922,000 | 2,212,000 | 2,565,000 | 2,736,000 |
lease obligation - operating, short-term | 264,000 | 254,000 | 239,000 | 231,000 | 190,000 | 184,000 | 176,000 | 248,000 | 267,000 | 419,000 | 567,000 | 594,000 | 553,000 | 356,000 | 476,000 | 497,000 | 485,000 | 472,000 | ||||||||||||
other current liabilities | 58,000 | 212,000 | 52,000 | 162,000 | 47,000 | 222,000 | 56,000 | 224,000 | 66,000 | 129,000 | 42,000 | 528,000 | 28,000 | 71,000 | 26,000 | 4,000 | ||||||||||||||
total current liabilities | 20,430,000 | 16,312,000 | 14,876,000 | 15,264,000 | 12,930,000 | 12,318,000 | 13,134,000 | 10,951,000 | 6,635,000 | 7,735,000 | 7,416,000 | 17,176,000 | 15,540,000 | 14,175,000 | 14,846,000 | 14,205,000 | 11,888,000 | 9,648,000 | 9,321,000 | 7,197,000 | 5,929,000 | 4,663,000 | 5,237,000 | 8,104,000 | 13,532,000 | 10,096,000 | 6,673,000 | 7,430,000 | 7,463,000 | 5,800,000 |
term loan, long-term | 51,200,000 | 51,050,000 | 51,350,000 | 51,099,000 | 39,990,000 | 39,385,000 | 38,811,000 | 38,262,000 | 37,741,000 | 37,252,000 | 36,794,000 | 2,463,000 | 4,913,000 | 7,354,000 | 9,777,000 | 12,156,000 | 14,515,000 | 16,858,000 | ||||||||||||
revenue purchase and sale liability | 28,957,000 | 27,675,000 | 26,869,000 | 26,830,000 | ||||||||||||||||||||||||||
lease obligation - operating, long-term | 984,000 | 1,053,000 | 1,104,000 | 1,167,000 | 1,184,000 | 1,233,000 | 1,282,000 | 1,303,000 | 4,000 | 5,000 | 7,000 | 114,000 | 271,000 | 10,000 | 99,000 | 229,000 | 356,000 | |||||||||||||
total liabilities | 101,571,000 | 96,090,000 | 94,199,000 | 94,360,000 | 56,208,000 | 53,888,000 | 57,261,000 | 56,955,000 | 50,744,000 | 51,564,000 | 51,762,000 | 17,290,000 | 18,705,000 | 19,500,000 | 22,567,000 | 24,421,000 | 24,572,000 | 24,778,000 | 26,878,000 | 27,145,000 | 25,860,000 | 25,384,000 | 25,918,000 | 28,780,000 | 19,990,000 | 17,189,000 | 15,011,000 | 15,429,000 | 16,417,000 | 15,708,000 |
commitments and contingencies | ||||||||||||||||||||||||||||||
stockholders’ equity | ||||||||||||||||||||||||||||||
preferred stock, 0.0001 par value... | ||||||||||||||||||||||||||||||
common stock, 0.0001 par value... | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | |||||||
additional paid-in capital | 382,939,000 | 381,104,000 | 379,809,000 | 378,353,000 | 321,790,000 | 320,016,000 | 318,561,000 | 316,678,000 | 315,329,000 | 313,541,000 | 298,934,000 | 248,395,000 | 247,587,000 | 246,823,000 | 246,166,000 | 245,487,000 | 244,868,000 | 244,279,000 | 243,830,000 | 243,684,000 | 242,898,000 | 191,649,000 | 180,818,000 | 176,524,000 | 175,900,000 | 175,574,000 | 175,201,000 | 174,748,000 | 174,189,000 | 173,690,000 |
accumulated deficit | -404,260,000 | -386,236,000 | -366,494,000 | -347,649,000 | -312,544,000 | -295,454,000 | -281,346,000 | -267,534,000 | -251,900,000 | -237,746,000 | -226,536,000 | -217,288,000 | -207,126,000 | -197,429,000 | -189,698,000 | -182,380,000 | -175,828,000 | -168,766,000 | -161,664,000 | -153,880,000 | -144,842,000 | -136,547,000 | -129,455,000 | -118,640,000 | -112,433,000 | -105,178,000 | -96,459,000 | -91,360,000 | -85,599,000 | -75,748,000 |
total stockholders’ equity | -21,316,000 | -5,127,000 | 13,320,000 | 30,709,000 | 9,250,000 | 24,566,000 | 37,218,000 | 49,146,000 | 63,427,000 | 75,807,000 | 72,433,000 | 31,110,000 | 40,457,000 | 49,393,000 | 56,470,000 | 63,110,000 | 69,043,000 | 75,515,000 | 82,170,000 | 89,815,000 | 98,059,000 | 55,104,000 | 51,365,000 | 57,886,000 | 63,469,000 | 70,398,000 | 78,744,000 | 83,390,000 | 88,592,000 | 97,944,000 |
total liabilities and stockholders’ equity | 80,255,000 | 90,963,000 | 107,519,000 | 125,069,000 | 65,458,000 | 78,454,000 | 94,479,000 | 106,101,000 | 114,171,000 | 127,371,000 | 124,195,000 | 48,400,000 | 59,162,000 | 68,893,000 | 79,037,000 | 87,531,000 | 93,615,000 | 100,293,000 | 109,048,000 | 116,960,000 | 123,919,000 | 80,488,000 | 77,283,000 | 86,666,000 | 83,459,000 | 87,587,000 | 93,755,000 | 98,819,000 | 105,009,000 | 113,652,000 |
short-term investments | 29,199,000 | 55,156,000 | 31,527,000 | 40,618,000 | 47,125,000 | 3,897,000 | 14,673,000 | 13,788,000 | 1,010,000 | 5,515,000 | 15,052,000 | 20,490,000 | 33,276,000 | |||||||||||||||||
derivative liability | 1,841,000 | 733,000 | 3,857,000 | 6,303,000 | 6,267,000 | 6,510,000 | 7,517,000 | 795,000 | 765,000 | 766,000 | ||||||||||||||||||||
other liabilities | 263,000 | 219,000 | 177,000 | 136,000 | 97,000 | 62,000 | 28,000 | 431,000 | 402,000 | 367,000 | 340,000 | 299,000 | 259,000 | 219,000 | 178,000 | 138,000 | 98,000 | 58,000 | 16,000 | 216,000 | 189,000 | 159,000 | 130,000 | 109,000 | 87,000 | |||||
common stock; 0.0001 par value... | 5,000 | 4,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | |||||||||||||||||||||||
accumulated other comprehensive loss | -7,000 | -4,000 | ||||||||||||||||||||||||||||
accumulated other comprehensive income | -1,000 | -2,000 | -6,000 | 8,000 | 32,000 | |||||||||||||||||||||||||
restricted cash | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | 182,000 | ||||||||||||
term loan, short-term | 9,880,000 | 9,851,000 | 9,826,000 | 9,805,000 | 9,777,000 | 7,293,000 | 4,838,000 | 2,408,000 | ||||||||||||||||||||||
other current assets | 340,000 | 331,000 | 59,000 | 24,000 | 11,000 | 75,000 | 102,000 | 121,000 | 146,000 | 12,000 | 59,000 | 94,000 | 128,000 | 148,000 | 169,000 | 179,000 | 97,000 | 151,000 | 135,000 | |||||||||||
accumulated other comprehensive gain | -1,000 | -1,000 | 1,000 | 8,000 | ||||||||||||||||||||||||||
vat receivable | 112,000 | 298,000 | 305,000 | 310,000 | 303,000 | 500,000 | 494,000 | 479,000 | 454,000 | 438,000 | 830,000 | |||||||||||||||||||
current portion of lease obligation - operating | 460,000 | 421,000 | 407,000 | 366,000 | 353,000 | 341,000 | 309,000 | 276,000 | ||||||||||||||||||||||
long-term lease obligation - operating | 480,000 | |||||||||||||||||||||||||||||
short term investments | 70,061,000 | 40,469,000 | ||||||||||||||||||||||||||||
lease obligation - operating, short term | 448,000 | 435,000 | 393,000 | 379,000 | ||||||||||||||||||||||||||
term loan, long term | 19,170,000 | 19,076,000 | 18,996,000 | 18,915,000 | 18,842,000 | 5,086,000 | 5,649,000 | 6,826,000 | 6,421,000 | 7,331,000 | 8,222,000 | |||||||||||||||||||
lease obligation - operating, long term | 600,000 | 717,000 | 1,052,000 | 1,156,000 | ||||||||||||||||||||||||||
long term lease obligation - operating | 832,000 | 943,000 | 1,255,000 | 1,353,000 | 1,448,000 | 1,514,000 | 1,599,000 | |||||||||||||||||||||||
term loan, short term | 4,624,000 | 4,035,000 | 2,811,000 | 3,210,000 | 2,231,000 | 1,265,000 | ||||||||||||||||||||||||
right-of-use lease assets - operating (type b) | 1,506,000 | 1,582,000 | 1,629,000 | 1,702,000 | ||||||||||||||||||||||||||
cash | 100,768,000 | 109,280,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | |||||||||||||||||||||||||||||
net loss | -18,024,000 | -19,742,000 | -18,845,000 | -35,105,000 | -17,090,000 | -14,108,000 | -13,812,000 | -15,634,000 | -14,154,000 | -11,210,000 | -9,248,000 | -10,162,000 | -9,697,000 | -7,731,000 | -7,318,000 | -6,552,000 | -7,062,000 | -7,102,000 | -7,784,000 | -9,038,000 | -6,208,000 | -5,100,000 | -5,761,000 | ||||||
adjustments to reconcile net loss to cash from operating activities | |||||||||||||||||||||||||||||
depreciation expense | 4,000 | 4,000 | 4,000 | 5,000 | 5,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 9,000 | 10,000 | 9,000 | 9,000 | 8,000 | 10,000 | 8,000 | 8,000 | 9,000 | 8,000 | 9,000 | 8,000 | 10,000 | 9,000 | 10,000 | 9,000 | 10,000 | 9,000 | 10,000 |
amortization expense - right-of-use leased assets - operating | 60,000 | 59,000 | 47,000 | 45,000 | 103,000 | 99,000 | 111,000 | 108,000 | 119,000 | 93,000 | 103,000 | 102,000 | 101,000 | 98,000 | 95,000 | 93,000 | 90,000 | 87,000 | 82,000 | 80,000 | 79,000 | 76,000 | 74,000 | 73,000 | 71,000 | ||||
accretion on short-term investments | 0 | 0 | 0 | -120,000 | -542,000 | -699,000 | -354,000 | -517,000 | |||||||||||||||||||||
allowance for excess, damaged and obsolete inventory | 118,000 | 17,000 | 25,000 | 25,000 | 25,000 | 25,000 | |||||||||||||||||||||||
stock-based compensation | 1,519,000 | 1,295,000 | 1,285,000 | 1,226,000 | 1,491,000 | 1,440,000 | 1,416,000 | 1,281,000 | 1,179,000 | 980,000 | 737,000 | 785,000 | 680,000 | 636,000 | 637,000 | 619,000 | 589,000 | 521,000 | 127,000 | 744,000 | 621,000 | 508,000 | 333,000 | 326,000 | 355,000 | 453,000 | 563,000 | 497,000 | 622,000 |
non-cash interest expense | 0 | 297,000 | 649,000 | 616,000 | 590,000 | 559,000 | 524,000 | 493,000 | 575,000 | 91,000 | 104,000 | 114,000 | 144,000 | 147,000 | 136,000 | 127,000 | 137,000 | 134,000 | 125,000 | 121,000 | 87,000 | 93,000 | 80,000 | 96,000 | 90,000 | 98,000 | 90,000 | ||
fair value adjustment to term loan | 150,000 | -300,000 | 251,000 | ||||||||||||||||||||||||||
fair value adjustment to revenue purchase and sale liability | 2,560,000 | 1,752,000 | 1,812,000 | ||||||||||||||||||||||||||
fair value adjustment to derivative liability | 0 | -1,841,000 | 1,108,000 | -3,124,000 | -2,446,000 | 36,000 | -243,000 | -1,007,000 | 0 | 0 | 0 | 30,000 | |||||||||||||||||
changes in operating assets and liabilities | |||||||||||||||||||||||||||||
accounts receivable | -5,556,000 | -2,132,000 | -2,561,000 | -3,101,000 | -344,000 | -1,283,000 | -314,000 | -2,565,000 | 1,394,000 | -3,004,000 | |||||||||||||||||||
inventory | -550,000 | -255,000 | 4,181,000 | -2,824,000 | -5,761,000 | -758,000 | -1,716,000 | -1,291,000 | -2,212,000 | -2,390,000 | |||||||||||||||||||
prepaid expenses and other assets | -105,000 | 775,000 | -30,000 | -708,000 | -917,000 | 422,000 | -646,000 | 411,000 | 717,000 | -261,000 | -1,691,000 | -5,000 | 622,000 | 187,000 | -1,175,000 | 798,000 | 262,000 | -119,000 | -1,435,000 | 1,930,000 | 461,000 | -720,000 | 981,000 | 126,000 | -19,000 | -884,000 | 664,000 | 90,000 | -703,000 |
accounts payable, accrued expenses and other liabilities | 3,713,000 | 1,388,000 | -1,426,000 | 2,320,000 | 560,000 | -862,000 | 2,161,000 | 4,179,000 | -1,101,000 | 317,000 | 439,000 | 993,000 | 1,016,000 | -681,000 | 499,000 | -296,000 | -341,000 | -2,227,000 | -406,000 | 1,275,000 | 1,028,000 | -685,000 | -866,000 | 2,710,000 | 2,096,000 | -451,000 | -1,105,000 | 611,000 | -432,000 |
net cash from operating activities | -16,111,000 | -17,139,000 | -17,424,000 | -20,227,000 | -17,701,000 | -13,451,000 | -14,141,000 | -16,494,000 | -8,196,000 | -7,175,000 | -7,369,000 | -5,167,000 | -6,271,000 | -8,615,000 | -4,808,000 | -5,962,000 | -7,743,000 | -5,578,000 | -3,911,000 | -6,118,000 | -5,465,000 | -8,472,000 | -9,074,000 | ||||||
capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15,000 | 0 | -6,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
free cash flows | -16,111,000 | -17,139,000 | -17,424,000 | -20,227,000 | -17,701,000 | -13,451,000 | -14,141,000 | -16,494,000 | -8,211,000 | -7,175,000 | -7,375,000 | -5,167,000 | -6,271,000 | -8,615,000 | -4,808,000 | -5,962,000 | -7,743,000 | -5,578,000 | -3,911,000 | -6,118,000 | -5,465,000 | -8,472,000 | -9,074,000 | ||||||
cash flows from investing activities | |||||||||||||||||||||||||||||
maturities of short-term investments | 0 | 0 | 1,000 | 29,319,000 | 26,500,000 | 16,000,000 | 21,100,000 | 7,000,000 | 3,900,000 | 10,800,000 | 4,500,000 | 10,550,000 | 9,400,000 | 16,700,000 | |||||||||||||||
net cash from investing activities | -9,000 | 1,000 | 29,319,000 | -22,925,000 | 9,427,000 | 7,000,000 | 10,784,000 | -861,000 | -12,790,000 | 9,521,000 | 5,403,000 | 12,705,000 | -29,692,000 | 0 | |||||||||||||||
cash flows from financing activities | |||||||||||||||||||||||||||||
payment on revenue purchase and sale liability | -940,000 | -972,000 | |||||||||||||||||||||||||||
proceeds from employee stock purchase plan | 171,000 | 0 | 282,000 | 0 | 89,000 | 0 | |||||||||||||||||||||||
proceeds from the exercise of vested stock options | 0 | 47,000 | 0 | 181,000 | 68,000 | 23,000 | 0 | 21,000 | 0 | 0 | 9,000 | 2,000 | 561,000 | 154,000 | 35,000 | 0 | 18,000 | 0 | 0 | 2,000 | 56,000 | ||||||||
settlement of restricted stock units for tax withholding obligations | 0 | 0 | 0 | -166,000 | |||||||||||||||||||||||||
net cash from financing activities | -624,000 | -972,000 | 70,413,000 | 283,000 | 15,000 | 68,000 | 611,000 | 13,704,000 | -2,477,000 | -2,416,000 | -2,479,000 | 0 | 0 | -72,000 | -82,000 | 49,952,000 | 10,458,000 | 9,673,000 | 0 | 18,000 | -4,000 | 1,000 | 56,000 | ||||||
net decrease in cash and cash equivalents | |||||||||||||||||||||||||||||
cash and cash equivalents at beginning of period | 0 | 75,655,000 | 0 | 0 | 46,814,000 | ||||||||||||||||||||||||
cash and cash equivalents at end of period | -16,735,000 | 57,544,000 | 52,980,000 | -19,943,000 | 58,447,000 | ||||||||||||||||||||||||
supplemental cash flow information | |||||||||||||||||||||||||||||
interest paid | 1,400,000 | 1,385,000 | 1,487,000 | 1,586,000 | 1,501,000 | 1,469,000 | 1,485,000 | 1,485,000 | 1,485,000 | 1,485,000 | 1,456,000 | 305,000 | 369,000 | 425,000 | 493,000 | 436,000 | 517,000 | 597,000 | 515,000 | 35,000 | 918,000 | 518,000 | 317,000 | 334,000 | 274,000 | 321,000 | 225,000 | 261,000 | 252,000 |
taxes paid | 114,000 | 8,000 | 37,000 | 46,000 | 119,000 | 9,000 | 52,000 | 40,000 | 87,000 | 69,000 | 76,000 | 0 | 78,000 | 36,000 | 40,000 | 41,000 | 83,000 | 42,000 | 82,000 | 0 | 40,000 | 90,000 | 166,000 | 15,000 | 24,000 | 189,000 | 70,000 | ||
net increase in cash and cash equivalents | -18,111,000 | 52,980,000 | -19,943,000 | 11,633,000 | |||||||||||||||||||||||||
adjustments to reconcile net loss to net cash from operating activities | |||||||||||||||||||||||||||||
loss on disposal of property and equipment | |||||||||||||||||||||||||||||
reduction in carrying value of operating right-of-use lease assets | 57,000 | 134,000 | |||||||||||||||||||||||||||
allowance for doubtful accounts | |||||||||||||||||||||||||||||
debt issuance costs | 0 | ||||||||||||||||||||||||||||
loss on extinguishment of debt | 0 | ||||||||||||||||||||||||||||
net cash flows from operating activities | |||||||||||||||||||||||||||||
purchases of property and equipment | -12,000 | -37,000 | 0 | 0 | -15,000 | 0 | -6,000 | 1,000 | 0 | ||||||||||||||||||||
purchases of short-term investments | 0 | -38,925,000 | -46,892,000 | -1,000 | -7,861,000 | -12,784,000 | 0 | -1,019,000 | -3,997,000 | -3,995,000 | |||||||||||||||||||
net cash flows from investing activities | |||||||||||||||||||||||||||||
proceeds from common stock offering, net of underwriter discounts and offering costs | 0 | ||||||||||||||||||||||||||||
proceeds from term loan | 0 | ||||||||||||||||||||||||||||
proceeds from revenue participation agreement | 0 | ||||||||||||||||||||||||||||
proceeds from at-the-market offering | 0 | 0 | 334,000 | 13,704,000 | 0 | 0 | 0 | 10,388,000 | |||||||||||||||||||||
principal payments on term loan | 0 | -10,000,000 | -2,500,000 | -2,500,000 | -2,500,000 | ||||||||||||||||||||||||
prepayment and legal fees | 0 | ||||||||||||||||||||||||||||
payment of term loan final fee | 0 | ||||||||||||||||||||||||||||
payments on revenue participation agreement | |||||||||||||||||||||||||||||
net cash flows from financing activities | |||||||||||||||||||||||||||||
net increase in cash | |||||||||||||||||||||||||||||
cash and cash equivalents, beginning of year | |||||||||||||||||||||||||||||
cash and cash equivalents, end of year | |||||||||||||||||||||||||||||
supplemental disclosure of non-cash activities | |||||||||||||||||||||||||||||
fair value of warrants issued | 0 | ||||||||||||||||||||||||||||
operating right-of-use asset received in exchange for lease obligations | 0 | 0 | |||||||||||||||||||||||||||
transfer of issuance costs from other noncurrent assets to equity | 0 | 0 | 3,000 | 76,000 | 135,000 | ||||||||||||||||||||||||
proceeds from the exercise of stock options | |||||||||||||||||||||||||||||
net decrease in cash | |||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of year | |||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, end of year | |||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | 4,095,000 | -3,911,000 | -6,100,000 | ||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of period | 0 | 0 | 71,243,000 | 0 | 0 | 74,450,000 | 0 | 0 | 72,001,000 | 0 | 0 | 72,806,000 | 0 | 0 | 89,660,000 | ||||||||||||||
cash, cash equivalents and restricted cash at end of period | -36,308,000 | -4,103,000 | 75,453,000 | 111,000 | -10,452,000 | 51,812,000 | 4,354,000 | -868,000 | 76,019,000 | -34,582,000 | 3,521,000 | 75,521,000 | 4,095,000 | -3,911,000 | 83,560,000 | ||||||||||||||
net increase in cash, cash equivalents and restricted cash | -4,103,000 | 4,210,000 | 111,000 | -10,452,000 | -22,638,000 | 4,354,000 | -868,000 | 4,018,000 | 3,521,000 | 2,715,000 | |||||||||||||||||||
accretion of discount (premium) on investments | |||||||||||||||||||||||||||||
settlements of restricted stock units for tax withholding obligations | 0 | 0 | -81,000 | -80,000 | 0 | -84,000 | |||||||||||||||||||||||
accretion of discount on investments | 5,000 | 46,000 | |||||||||||||||||||||||||||
accretion expense | 4,000 | 79,000 | |||||||||||||||||||||||||||
payment of term loan exit fee | 0 | 0 | |||||||||||||||||||||||||||
proceeds from common stock offering | -4,000 | ||||||||||||||||||||||||||||
supplemental non-cash information | |||||||||||||||||||||||||||||
proceeds from term loan, net of costs | |||||||||||||||||||||||||||||
issuance of derivative in connection with modification of term loan | |||||||||||||||||||||||||||||
purchases of short term investments | -29,692,000 | ||||||||||||||||||||||||||||
net income | -7,092,000 | -8,719,000 | -8,732,000 | ||||||||||||||||||||||||||
adjustments to reconcile net income to cash from operating activities | |||||||||||||||||||||||||||||
cash and cash equivalents | 75,339,000 | 83,378,000 | |||||||||||||||||||||||||||
restricted cash | 182,000 | 182,000 | |||||||||||||||||||||||||||
cash, cash equivalents and restricted cash | 75,521,000 | 83,560,000 | |||||||||||||||||||||||||||
costs related to initial public offering | -4,000 | ||||||||||||||||||||||||||||
proceeds from at-the-market offering, net of commissions | |||||||||||||||||||||||||||||
at-the-market offering costs | |||||||||||||||||||||||||||||
acquisition of right-of-use leased assets - operating, net of disposal | |||||||||||||||||||||||||||||
proceeds from issuance of series b convertible preferred stock | |||||||||||||||||||||||||||||
costs related to issuance of series b convertible preferred stock | |||||||||||||||||||||||||||||
proceeds from issuance of convertible notes | |||||||||||||||||||||||||||||
costs related to issuance of convertible notes | |||||||||||||||||||||||||||||
proceeds from the early exercise of stock options | |||||||||||||||||||||||||||||
purchase of restricted stock | |||||||||||||||||||||||||||||
conversion of convertible preferred stock into common stock | |||||||||||||||||||||||||||||
conversion of convertible notes into convertible preferred stock, including accrued interest | |||||||||||||||||||||||||||||
beneficial conversion feature of convertible notes | |||||||||||||||||||||||||||||
vesting of restricted stock | |||||||||||||||||||||||||||||
acquisition of right-of-use leased assets - operating (type b), net of disposal | 0 | ||||||||||||||||||||||||||||
net decrease in cash and restricted cash | -8,512,000 | -9,018,000 | |||||||||||||||||||||||||||
cash and restricted cash at beginning of period | 0 | 118,480,000 | |||||||||||||||||||||||||||
cash and restricted cash at end of period | -8,512,000 | 109,462,000 | |||||||||||||||||||||||||||
net income and comprehensive loss | -8,732,000 | ||||||||||||||||||||||||||||
weighted-average shares used for eps calculation | 18,535,432,000 | ||||||||||||||||||||||||||||
net income per share | -470 | ||||||||||||||||||||||||||||
fair value adjustments to series a purchase rights | |||||||||||||||||||||||||||||
proceeds from issuance of series a convertible preferred stock | |||||||||||||||||||||||||||||
costs related to issuance of series a convertible preferred stock | |||||||||||||||||||||||||||||
cash and restricted cash, beginning of year | |||||||||||||||||||||||||||||
cash and restricted cash, end of year | |||||||||||||||||||||||||||||
reclassification of series a purchase rights to series a convertible preferred stock |